TARS (Tarsus Pharmaceuticals) Defensive Interval Ratio


TARS Tarsus Pharmaceuticals Inc TARS
47 GF Score
Price $67.05
GF Value $204.06
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Defensive Interval Ratio?

TARS
47GF Score
Tarsus Pharmaceuticals Inc TARS
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $67.05 is trading 67.1% below its estimated GF Value™ of $204.06. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Defensive Interval Ratio:
  • GF Value™: $204.06 vs. price of $67.05 (67.1% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score

Get the complete analysis for TARS

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.05
Price
$204.06
GF Value